Insufficient cerebrospinal fluid penetration of tedizolid: a case report
JAC-Antimicrobial Resistance · 02.07.2025 · 7 (4)
DOI: 10.1093/jacamr/dlaf100 ↗Kurz gefasst
Fallbericht in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 08.07.2025. Verfasst von Xavier Brousse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, University Hospital of La Réunion, Saint-Pierre, Reunion Island 97410, France. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Tedizolid, a novel oxazolidinone developed for the treatment of skin and soft tissue infections, exhibits a longer half-life than linezolid, with reduced myelosuppression and neurotoxicity. However, its penetration into the cerebrospinal fluid (CSF) remains poorly characterized. Our case report evaluated the CSF penetration of tedizolid. Case presentation We present a case of parameningeal aseptic meningitis secondary to otogenic skull base osteomyelitis. Tedizolid concentrations in CSF and serum were measured using liquid chromatography and tandem mass spectrometry. The trough CSF concentration of tedizolid was below the limit of quantification, whereas the corresponding serum concentration was within the expected therapeutic range. A brief review of the literature corroborated the observation that CSF penetration of tedizolid was markedly lower than that of linezolid.
Conclusion
Considering the consistently low CSF concentrations of tedizolid, linezolid remains the preferred agent for the treatment of CNS infections.
Autor:innen und Institutionen
- Infectious Diseases Unit, University Hospital of La Réunion, Saint-Pierre, Reunion Island 97410, France.
- Infectious Diseases Unit, University Hospital of Bordeaux, Bordeaux F-33000, France.
- Pharmacology Department, AP-HP, Bichat Claude Bernard Hospital, Paris, France.
- Université Paris Cité, INSERM, IAME, UMR 1137, Paris F-75006, France.
- Clinical Pharmacy Department, University Hospital of Bordeaux, Bordeaux F-33000, France.
ORCID-Profile: Xavier Brousse, Minh P Lê, Marin Lahouati, Paul Petitgas
Zitieren
APA
Brousse, X., Lê, M. P., Lahouati, M., & Petitgas, P. (2025). Insufficient cerebrospinal fluid penetration of tedizolid: a case report. JAC-Antimicrobial Resistance, 7(4). https://doi.org/10.1093/jacamr/dlaf100
Vancouver
Brousse X, Lê MP, Lahouati M, Petitgas P. Insufficient cerebrospinal fluid penetration of tedizolid: a case report. JAC-Antimicrobial Resistance. 2025;7(4). doi:10.1093/jacamr/dlaf100
BibTeX
@article{Brousse2025,
author = {Brousse, Xavier and Lê, Minh P and Lahouati, Marin and Petitgas, Paul},
title = {Insufficient cerebrospinal fluid penetration of tedizolid: a case report},
journal = {JAC-Antimicrobial Resistance},
year = {2025},
volume = {7},
number = {4},
doi = {10.1093/jacamr/dlaf100}
}
EUVIMED